ESMO Congress 2021 - Mini oral session - Melanoma and other skin tumours
ESMO
9/20/21, 8:30 PM
Europe/Paris GMT+2
Description
1038MO - Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial
Presentation Number
1038MO
Speakers
- Ivan Marquez-Rodas (Madrid, Spain)
Lecture Time
17:30 - 17:35
1039MO - CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM)
Presentation Number
1039MO
Speakers
- Kim A. Margolin (Duarte, CA, United States of America)
Lecture Time
17:35 - 17:40
Discussion 1038MO and 1039MO
Speakers
- Teresa Petrella (Toronto, Ontario, Canada)
Lecture Time
17:40 - 17:50
LBA39 - Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study
Presentation Number
LBA39
Speakers
- Christian U. Blank (Amsterdam, Netherlands)
Lecture Time
17:50 - 17:55
LBA40 - SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study
Presentation Number
LBA40
Speakers
- Paolo A. Ascierto (Napoli, Italy)
Lecture Time
17:55 - 18:00
1041MO - 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma
Presentation Number
1041MO
Speakers
- Reinhard Dummer (Zurich, Switzerland)
Lecture Time
18:00 - 18:05
Discussion LBA39, LBA40 and 1041MO
Speakers
- Teresa Troiani (Napoli, Italy)
Lecture Time
Previous registration necessary?
NO
YES
Simultaneous translation ?
NO
YES
Will it be recorded?
NO
YES
Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial, CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM), Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study, SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study, 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma
Inglês
Speakers
Ivan Marquez-Rodas, Kim A. Margolin, Teresa Petrella, Christian U. Blank, Paolo A. Ascierto, Reinhard Dummer, Teresa Troiani
Link to the Event
Banner to the Event
Register your event here
Already have an account? LOGIN HERE. If You don't have an account you need to create a free account.